Therefore, further research on the regulation of PD-L1 expression in breast cancer cells will shed light on the mechanism underlying breast cancer cell immune evasion and help increase immune checkpoint therapy’s clinical effectiveness. This evidence concerns the gene CD274 and breast carcinoma.